MOR101 Biosimilar – Anti-ICAM1, CD54 mAb – Research Grade

Introduction

MOR101 Biosimilar – Anti-ICAM1, CD54 mAb – Research Grade is a monoclonal antibody (mAb) that targets the intercellular adhesion molecule-1 (ICAM-1), also known as CD54. This biosimilar is a highly specific and potent therapeutic agent with potential applications in various diseases.

Structure

MOR101 Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to its target, ICAM-1, while the constant region provides effector functions.

Activity

ICAM-1 is a cell surface glycoprotein that plays a crucial role in inflammation and immune response. It is expressed on various cell types, including endothelial cells, leukocytes, and epithelial cells. ICAM-1 is involved in leukocyte recruitment and adhesion to the endothelium, which is an essential step in the inflammatory process.

MOR101 Biosimilar binds specifically to ICAM-1, blocking its interaction with leukocytes. This prevents the adhesion of leukocytes to the endothelium and reduces the recruitment of inflammatory cells to the site of inflammation. This mechanism of action makes MOR101 Biosimilar an effective anti-inflammatory agent.

Application

MOR101 Biosimilar has potential applications in various diseases that involve inflammation and immune response. It can be used as a therapeutic agent in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

In rheumatoid arthritis, ICAM-1 plays a crucial role in the migration and activation of immune cells, leading to joint inflammation and damage. By targeting ICAM-1, MOR101 Biosimilar can reduce the recruitment of inflammatory cells to the joints, thereby alleviating the symptoms of rheumatoid arthritis.

Psoriasis is a chronic inflammatory skin disease characterized by the infiltration of immune cells into the skin. ICAM-1 is upregulated in psoriatic skin, and its inhibition by MOR101 Biosimilar can reduce the infiltration of immune cells, leading to an improvement in psoriatic lesions.

Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract. ICAM-1 is involved in the recruitment of leukocytes to the intestinal mucosa, which contributes to the pathogenesis of IBD. MOR101 Biosimilar can inhibit this process and potentially alleviate the symptoms of IBD.

Research Grade

MOR101 Biosimilar is available in a research grade, which is suitable for in vitro and in vivo studies. This grade is produced using advanced recombinant DNA technology, ensuring high purity and consistency. It is also free from animal-derived components, making it suitable for use in various research applications.

Conclusion

In conclusion, MOR101 Biosimilar – Anti-ICAM1, CD54 mAb – Research Grade is a highly specific and potent therapeutic agent that targets ICAM-1. Its ability to inhibit the interaction between ICAM-1 and leukocytes makes it a promising treatment for various inflammatory and immune-related diseases. The availability of a research grade makes it a valuable tool for further studies on its therapeutic potential.